

# \$6.3+ Bn Insomnia Market to Grow at 3.9% CAGR, Globally, by 2030, North America claimed the largest share of the market

PORTLAND, OREGON, UNITED STATES, November 6, 2023 /EINPresswire.com/ -- In a recent analysis conducted by Allied Market Research, the worldwide [Insomnia Market](#) demonstrated remarkable growth, surging from a valuation of \$4.3 billion in 2020 to a projected \$6.3 billion by the year 2030. This upward trajectory is attributed to a steady compound annual growth rate (CAGR) of 3.9% from 2021 to 2030, indicating a promising future for this sector.



The comprehensive report furnished by Allied Market Research delves deep into this burgeoning market, offering insights into not only the financial aspects but also the strategic landscape. By identifying the prime investment opportunities, successful strategies, driving forces, and potential openings, the report equips stakeholders with essential knowledge to navigate this dynamic market.

For more information, please visit: <https://www.alliedmarketresearch.com/request-sample/2373>

The global insomnia market is experiencing significant growth, driven by several key factors. The increasing prevalence of various sleep disorders, such as insomnia and parasomnias, is a primary catalyst for this growth. Furthermore, the rise in mental depression and other painful conditions has heightened the demand for effective sleep solutions, contributing to the expansion of the market.

Advancements in non-pharmacological therapy for sleep disorders have played a pivotal role in the market's growth trajectory. These innovative approaches offer alternatives to traditional medication, appealing to individuals seeking more holistic and sustainable solutions for their sleep-related issues. Additionally, the continuous introduction of new products and therapies in the market has further fueled its expansion.

COVID-19 -

The COVID-19 pandemic has had a profound impact on global society and various sectors, including the insomnia market. The outbreak of the pandemic led to widespread job losses, economic instability, and significant lifestyle changes for many individuals. As a consequence, a considerable number of people experienced heightened levels of stress, anxiety, and depression due to the uncertainty and challenges brought about by the pandemic.

The correlation between mental health issues, such as depression and stress, and sleep disorders like insomnia is well-documented. The increased psychological distress caused by the pandemic has, indeed, amplified the demand for insomnia drugs and therapies. Individuals struggling with sleep disturbances turned to these treatments to alleviate their sleep-related problems and regain a sense of normalcy in their lives.

Global insomnia market size and forecast by COVID-19? Visit our website for more details:

<https://www.alliedmarketresearch.com/purchase-enquiry/2373>

Geographically, the global insomnia market exhibited distinct patterns in 2020, with North America emerging as the dominant region, capturing a significant share of nearly three-fifths of the global market. This underscores the robust presence and demand for insomnia-related products and treatments in North America.

Conversely, the Asia-Pacific region is poised to be a noteworthy growth center, projected to experience the fastest Compound Annual Growth Rate (CAGR) of 5.5% throughout the forecast period. This surge in the Asia-Pacific region highlights the increasing recognition of sleep-related disorders, changing lifestyles, and the growing awareness of available treatments.

The data indicates that North America continues to be a pivotal market for insomnia solutions, while the Asia-Pacific region is emerging as a significant growth hub, signaling promising opportunities for industry stakeholders to expand their presence and cater to the evolving needs of these distinct but burgeoning markets.

Top insomnia drugs

1. zydus cadila
2. merck kgaa
3. darmstadt
4. germany
5. EISAI
6. VIATRIS
7. Vanda Pharmaceuticals
8. MINERVA NEUROSCIENCES

9. Sanofi
10. Takeda Pharmaceutical Company
11. CURRAX PHARMACEUTICALS
12. Pfizer

The key market players analyzed in the global insomnia market report include **Novartis Pharmaceuticals Corporation**, **Roche**, **Abbott Laboratories**, **Novartis** & **Roche**, **Novartis**, **Roche**, **Novartis** Pharmaceuticals Corporation, **Roche**, **Novartis** Pharmaceuticals Corporation, **Roche**, **Novartis** Pharmaceuticals Corporation, **Roche** Pharmaceuticals (Novartis Inc). These market players have adhered to several strategies including partnership, expansion, collaboration, joint ventures, and others to prove their flair in the industry.

Novartis Pharmaceuticals Corporation?

1. What are the leading causes of insomnia, and how do they impact the market?
2. Can you provide insights into the most innovative non-pharmacological therapies for insomnia?
3. How has the telemedicine industry affected the treatment of insomnia?
4. What role do wearable sleep-tracking devices play in the insomnia market?
5. Are there any specific demographic trends driving the demand for insomnia treatments?
6. How does the competitive landscape differ between pharmaceutical and non-pharmaceutical insomnia treatments?
7. What regulatory changes or guidelines have impacted the insomnia market in recent years?
8. How do cultural factors influence the prevalence and treatment of insomnia worldwide?
9. What are the key challenges associated with diagnosing and treating insomnia in pediatric patients?
10. Can you elaborate on the market potential for natural remedies and herbal supplements for insomnia?
11. How has the integration of artificial intelligence and machine learning impacted insomnia diagnosis and treatment?
12. Are there any emerging trends in the use of virtual reality or augmented reality for insomnia therapy?
13. What is the impact of comorbid conditions like sleep apnea on the insomnia market?
14. How do different socioeconomic factors affect access to and adoption of insomnia treatments?
15. Can you provide insights into the role of nutrition and dietary habits in managing insomnia?
16. How has the COVID-19 pandemic influenced the acceptance of remote sleep monitoring and treatment options?
17. What is the outlook for the development of personalized insomnia treatment plans?
18. Are there notable partnerships or collaborations within the insomnia market that have driven innovation?
19. How are regulatory bodies addressing the potential misuse or overuse of prescription

insomnia medications?

20. Can you discuss the potential impact of emerging technologies, such as brain-computer interfaces, on the future of insomnia treatment?

□□□ □□□□□□□□□□ □□□□□□□□□□ - <https://www.alliedmarketresearch.com/purchase-enquiry/2373>

David Correa

Allied Analytics LLP

+ +1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/666607414>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.